QQQ   348.82 (-1.70%)
AAPL   177.82 (-0.78%)
MSFT   323.38 (-3.09%)
META   263.60 (-2.77%)
GOOGL   122.50 (-3.78%)
AMZN   121.23 (-4.25%)
TSLA   224.57 (+1.47%)
NVDA   374.75 (-3.05%)
NIO   7.76 (-1.52%)
BABA   85.29 (-1.63%)
AMD   117.83 (-5.15%)
T   16.09 (+2.68%)
F   13.59 (+5.11%)
MU   67.06 (-0.71%)
CGC   0.72 (-2.69%)
GE   106.08 (+0.59%)
DIS   92.53 (+0.40%)
AMC   4.73 (+1.94%)
PFE   38.89 (+1.36%)
PYPL   64.04 (-1.51%)
NFLX   399.77 (+0.12%)
QQQ   348.82 (-1.70%)
AAPL   177.82 (-0.78%)
MSFT   323.38 (-3.09%)
META   263.60 (-2.77%)
GOOGL   122.50 (-3.78%)
AMZN   121.23 (-4.25%)
TSLA   224.57 (+1.47%)
NVDA   374.75 (-3.05%)
NIO   7.76 (-1.52%)
BABA   85.29 (-1.63%)
AMD   117.83 (-5.15%)
T   16.09 (+2.68%)
F   13.59 (+5.11%)
MU   67.06 (-0.71%)
CGC   0.72 (-2.69%)
GE   106.08 (+0.59%)
DIS   92.53 (+0.40%)
AMC   4.73 (+1.94%)
PFE   38.89 (+1.36%)
PYPL   64.04 (-1.51%)
NFLX   399.77 (+0.12%)
QQQ   348.82 (-1.70%)
AAPL   177.82 (-0.78%)
MSFT   323.38 (-3.09%)
META   263.60 (-2.77%)
GOOGL   122.50 (-3.78%)
AMZN   121.23 (-4.25%)
TSLA   224.57 (+1.47%)
NVDA   374.75 (-3.05%)
NIO   7.76 (-1.52%)
BABA   85.29 (-1.63%)
AMD   117.83 (-5.15%)
T   16.09 (+2.68%)
F   13.59 (+5.11%)
MU   67.06 (-0.71%)
CGC   0.72 (-2.69%)
GE   106.08 (+0.59%)
DIS   92.53 (+0.40%)
AMC   4.73 (+1.94%)
PFE   38.89 (+1.36%)
PYPL   64.04 (-1.51%)
NFLX   399.77 (+0.12%)
QQQ   348.82 (-1.70%)
AAPL   177.82 (-0.78%)
MSFT   323.38 (-3.09%)
META   263.60 (-2.77%)
GOOGL   122.50 (-3.78%)
AMZN   121.23 (-4.25%)
TSLA   224.57 (+1.47%)
NVDA   374.75 (-3.05%)
NIO   7.76 (-1.52%)
BABA   85.29 (-1.63%)
AMD   117.83 (-5.15%)
T   16.09 (+2.68%)
F   13.59 (+5.11%)
MU   67.06 (-0.71%)
CGC   0.72 (-2.69%)
GE   106.08 (+0.59%)
DIS   92.53 (+0.40%)
AMC   4.73 (+1.94%)
PFE   38.89 (+1.36%)
PYPL   64.04 (-1.51%)
NFLX   399.77 (+0.12%)
LON:RENX

Renalytix (RENX) Share Forecast, Price & News

GBX 87.50
0.00 (0.00%)
(As of 06/7/2023 ET)
Compare
Today's Range
85
▼
88.75
50-Day Range
81
▼
95.20
52-Week Range
44
▼
192.49
Volume
8,977 shs
Average Volume
67,281 shs
Market Capitalization
£82.06 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
ProfileChartCompetitorsInsider TradesHeadlines

RENX stock logo

About Renalytix (LON:RENX) Stock

Renalytix Plc develops artificial intelligence-enabled in vitro diagnostic solutions for kidney diseases. The company offers KidneyIntelX, a diagnostic platform that employs an artificial intelligence-enabled algorithm that combines various data inputs, including validated blood-based biomarkers, inherited genetics and personalized patient data from electronic health record systems to generate a unique patient risk score. Its products are used in kidney disease diagnosis and prognosis, clinical care, patient stratification for drug clinical trials, and drug target discovery. Renalytix AI plc has a license agreement with Mount Sinai Health System to develop and commercialize licensed products in connection with the application of artificial intelligence for the diagnosis of kidney disease; Joslin Diabetes Center, Inc. for developing and commercializing products for diagnosing and predicting kidney disease using biomarkers; and Kantaro Biosciences LLC for developing and commercializing laboratory tests for the detection of antibodies against SARS-CoV-2. The company also has a partnership agreement with Atrium Health, Wake Forest Baptist Health, and Wake Forest School of Medicine to implement an advanced clinical care model designed to improve kidney health and reduce kidney disease progression and kidney failure in high-risk populations. The company was formerly known as Renalytix AI plc and changed its name to Renalytix Plc in June 2021. Renalytix Plc was incorporated in 2018 and is headquartered in New York, New York.

Receive RENX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Renalytix and its competitors with MarketBeat's FREE daily newsletter.

RENX Stock News Headlines

May 31, 2023 | uk.movies.yahoo.com
Is the Renalytix share price a bargain or a falling knife?
April 20, 2023 | marketwatch.com
New Published Real-World Evidence Shows KidneyIntelX(TM) Utility
June 7, 2023 | Behind the Markets (Ad)
The single greatest medical breakthrough of all time?
We are on the cusp of a medical breakthrough. And soon, this single breakthrough could lead to the cure of over 6,000 genetic diseases, including Alzheimer's, heart disease, and even cancer! This reminds me of Amgen, where early investors made as much as 46,751% when they released their revolutionary drug to the market.
April 19, 2023 | finance.yahoo.com
New Published Real-World Evidence Shows KidneyIntelX™ Utility
April 12, 2023 | finance.yahoo.com
Data Supportive of KidneyIntelX Utility in Minorities and Veterans to Be Presented at the National Kidney Foundation Spring Clinical Meeting
March 30, 2023 | finance.yahoo.com
Renalytix Reports Second Quarter and First Half Fiscal Year 2023 Financial Results
March 21, 2023 | marketwatch.com
Renalytix Shares Fall on Delay to FDA Marketing Authorization Decision on KidneyIntelX
February 9, 2023 | finance.yahoo.com
Renalytix to Participate in the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference
June 7, 2023 | Behind the Markets (Ad)
How A.I. Could Make Most 21st Century Diseases EXTINCT
On December 22, 2022, AI discovered a new treatment for multiple myeloma... in just 4 months... On March 19, 2023, AI discovered a new drug for liver cancer... in only 30 days... There's one small-cap at the center of it all. Bill Gates owns 7 million shares... Billionaire hedge-fund manager Steve Cohen owns 1.4 million shares...
February 8, 2023 | finance.yahoo.com
Renalytix announces a c.$20.3 million private placement
January 26, 2023 | marketwatch.com
Renalytix Shares Rise on $10 Mln Grant Award to Advance Chronic Kidney Disease Treatment
January 26, 2023 | finance.yahoo.com
Renalytix and Partners Awarded $10 Million Horizon Europe Grant to Advance Personalized Medicine in Treating CKD Throughout Europe and the United States
January 9, 2023 | finance.yahoo.com
Renalytix Completes Agreement with Veterans Administration to Integrate KidneyIntelX Testing across all Electronic Health Record systems
December 1, 2022 | finance.yahoo.com
Primary Care Use of KidneyIntelX in Early Stage CKD Improved Clinical Care Delivery and Outcomes
November 30, 2022 | finanznachrichten.de
Renalytix AI, Inc.: Renalytix Reports Financial Results for First Quarter of Fiscal Year 2023
November 30, 2022 | msn.com
What’s going on with the Renalytix share price?
October 31, 2022 | finanznachrichten.de
Renalytix plc: Renalytix Reports Full Year Fiscal 2022 Results
October 24, 2022 | finance.yahoo.com
Renalytix to Report Financial Results for Fourth Quarter and Full Year Fiscal 2022 on October 31
September 20, 2022 | finance.yahoo.com
Renalytix Announces Change to Board of Directors
August 17, 2022 | uk.finance.yahoo.com
Renalytix Plc (RENX.L)
August 8, 2022 | finance.yahoo.com
Data Results Published in American Journal of Managed Care demonstrate adoption and clinical utility of KidneyIntelX™ with Primary Care Physicians
June 30, 2022 | fool.co.uk
Here’s why the Renalytix share price is tanking
June 30, 2022 | finance.yahoo.com
Renalytix Reports Financial Results for Third Quarter of Fiscal Year 2022
June 16, 2022 | uk.finance.yahoo.com
The Renalytix share price – where next?
June 10, 2022 | finance.yahoo.com
1,112 Patient Study Demonstrates Clinical Utility and Care Benefits of KidneyIntelX™ Risk Stratification in Stage 1 to 3 Diabetic Kidney Disease Patients
June 6, 2022 | finance.yahoo.com
KidneyIntelX™ Demonstrates Ability to Assess Risk of Heart Failure Hospitalization and Death in Large International Diabetic Kidney Disease Patient Cohort
June 3, 2022 | stockhouse.com
Renalytix Announces Two Data Presentations on KidneyIntelX(TM) at American Diabetes Association 82nd Scientific Sessions®
See More Headlines

RENX Price History

Industry, Sector and Symbol

Stock Exchange
LON
Industry
Diagnostics & Research
Sub-Industry
N/A
Sector
Medical
Current Symbol
LON:RENX
CUSIP
N/A
CIK
N/A
Web
www.renalytixai.com
Phone
44 20 3139 2910
Fax
N/A
Employees
51
Year Founded
N/A

Profitability

EPS (Most Recent Fiscal Year)
GBX (0.64)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
£-44,940,000.00
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-97.21%
Return on Assets
-48.55%

Debt

Debt-to-Equity Ratio
58.94
Current Ratio
1.96
Quick Ratio
2.42

Sales & Book Value

Annual Sales
£3.80 million
Price / Sales
21.22
Cash Flow
GBX 46.86 per share
Price / Cash Flow
1.84
Book Value
GBX 28 per share
Price / Book
3.07

Miscellaneous

Outstanding Shares
93,780,000
Free Float
N/A
Market Cap
£80.65 million
Optionable
Not Optionable
Beta
1.97

Key Executives

  • Mr. James R. McCullough M.B.A. (Age 55)
    CEO & Exec. Director
    Comp: $648k
  • Mr. Fergus Fleming (Age 56)
    CTO & Exec. Director
    Comp: $449k
  • Mr. Thomas H. McLain CPA (Age 64)
    M.B.A, Pres
  • Mr. Oliver James Sterling III
    Chief Financial Officer
  • Ms. Andria Parks-Herrera
    VP of Marketing
  • Ms. Jean M. Casner (Age 64)
    Sr. VP & Chief HR Officer
  • Mr. Baljit Singh
    Head of Clinical Operations
  • Dr. Michael J. Donovan M.D. (Age 69)
    Ph.D., Chief Medical Officer
  • Mr. Salim Hamir F.C.A.
    Company Sec.

Key Competitors

View All Competitors













RENX Stock - Frequently Asked Questions

How have RENX shares performed in 2023?

Renalytix's stock was trading at GBX 72.50 at the beginning of the year. Since then, RENX shares have increased by 18.6% and is now trading at GBX 86.
View the best growth stocks for 2023 here.

What other stocks do shareholders of Renalytix own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Renalytix investors own include United Microelectronics (UMC), Teva Pharmaceutical Industries (TEVA), SSP Group (SSPG), Sarepta Therapeutics (SRPT), Redrow (RDW), QUALCOMM (QCOM), Lloyds Banking Group (LLOY), Entain PLC (GVC.L) (GVC), Gamma Communications (GAMA) and eHealth (EHTH).

What is Renalytix's stock symbol?

Renalytix trades on the London Stock Exchange (LON) under the ticker symbol "RENX."

How do I buy shares of Renalytix?

Shares of RENX stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.

What is Renalytix's stock price today?

One share of RENX stock can currently be purchased for approximately GBX 86.

How much money does Renalytix make?

Renalytix (LON:RENX) has a market capitalization of £80.65 million and generates £3.80 million in revenue each year. The company earns £-44,940,000.00 in net income (profit) each year or GBX (0.64) on an earnings per share basis.

How can I contact Renalytix?

The official website for the company is www.renalytixai.com. The company can be reached via phone at 44 20 3139 2910.

This page (LON:RENX) was last updated on 6/7/2023 by MarketBeat.com Staff

My Account -